SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-166299
Filing Date
2024-06-24
Accepted
2024-06-24 07:23:01
Documents
13
Period of Report
2024-06-24
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d836286d8k.htm   iXBRL 8-K 31080
  Complete submission text file 0001193125-24-166299.txt   154548

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rgls-20240624.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20240624_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20240624_pre.xml EX-101.PRE 11266
16 EXTRACTED XBRL INSTANCE DOCUMENT d836286d8k_htm.xml XML 3670
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 241062052
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)